| MATERIAL S AND ME THODS

| Patients
The G-SOX trial was a randomized, open-label, phase III study that compared the efficacy and safety of the SOX and CS treatment regimens in patients with curatively unresectable, advanced, or recurrent gastric cancer. 15 In total, 685 randomized patients were studied and data collected from January 2010 until
October 2011. The SOX regimen was confirmed to be non-inferior to the CS regimen. In the SOX regimen, S-1 was given orally for the 1st 2 wk of a 3-wk cycle, and oxaliplatin was infused at 100 mg/m 2 on day 1. In the CS regimen, S-1 was given for the 1st 3 wk of a 5-wk cycle, and cisplatin was administered at 60 mg/m 2 on day 8. The CCr was estimated using the Cockcroft-Gault equation. The proportion of female patients treated with SOX and CS was 24.0% (81/338) and 27.5% (92/335) in the safety analysis set (SAF), and 24.3% (81/333) and 27.3% (90/330) in the full analysis set (FAS), respectively.
| Statistical analysis
Median OS and PFS were estimated using the Kaplan-Meier method.
Differences in therapeutic efficacy between SOX and CS were tested using the log-rank test. Statistical significance was considered to be men treated with CS. In contrast, male patients treated with CS experienced thrombocytopenia more often (OR 0.51; P = .009). The mean relative dose intensity of S-1 in SOX was 75.4% in women and 81.4% in men (P = .032). No difference in efficacy was observed between women and men undergoing either regimen. Sex-related differences in adverse reactions during SOX and CS treatment were confirmed in this phase III study. Further translational research studies are warranted to pursue the cause of this difference.
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fluorouracil, gastric cancer, oxaliplatin, S-1, sex at a value of P < .05. The Cox proportional hazards model was used to estimate hazard ratios (HRs) of SOX compared with CS with 95% confidence intervals (CIs). Efficacy was analyzed in the FAS, which included patients who met the main inclusion criteria and none of the exclusion criteria in the SAF.
The incidence of adverse events in female or male patients during the 1st treatment cycle was compared between the two regimens using Fisher's exact test and logistic regression. Multivariate analyses for toxicities were also carried out using a logistic regression model. Adverse events were assessed in accordance with the Common Terminology Criteria for Adverse Events version 3.0.
Furthermore, treatment delivery was evaluated for both women and men in both treatment groups. Statistical analyses were performed using SAS version 9.3 software (SAS Institute).
| RE SULTS
Baseline characteristics of all patients enrolled in the G-SOX study were comparable between the two sexes and treatment groups. The numbers of histologically undifferentiated type gastric cancer were higher in women than in men (Table 1) .
| Safety
Adverse events are listed in TA B L E 2 Adverse events during the first cycle of treatment with S-1 plus oxaliplatin or S-1 plus cisplatin by creatinine clearance .006
Abbreviations: 95%CI, 95% confidence interval; CCr, creatinine clearance rate; CS, cisplatin plus S-1; OR, odds ratio; SOX, S-1 plus oxaliplatin. The median BMI of female patients treated with S-1 plus oxaliplatin or S-1 plus cisplatin were 20.4 kg/m 2 , and the BMI of males were 21.6 kg/m 2 .
Abbreviations: BMI, body mass index; CCr, creatinine clearance; CI, confidence interval; OR, odds ratio; PS, performance status.
an independent predictive marker of those toxicities (Table 3) .
Thrombocytopenia following CS treatment was also observed more frequently in patients aged 70 years or older as measured by multivariate analysis.
The incidences of nausea and vomiting were higher in women, even though aprepitant was not commonly administered to patients treated with SOX. Aprepitant was given to 9.3% of male patients and 11.1%
of female patients in the SOX group, and 74.5% of male patients and 73.9% of female patients in the CS group. Despite aprepitant administration, all grades of vomiting were still observed. Although the incidence of vomiting decreased to 22% (2/9) for women and 17% (4/24) for men, there was no difference in the incidence of vomiting between women and men (P = 1.0). The incidence of vomiting (39%; 28/72) in women was significantly higher than that in men (18%; 41/233) (P = .0003) in the SOX group when aprepitant was not given ( Table 4 ).
The mean relative dose intensities (RDIs) for S-1 during the three cycles of SOX were significantly lower in women (75.4%) than that in men (81.4%) (P = .032), while the RDIs for S-1 during the two cycles of CS were 84.0% in women and 79.6% in men (P = .081) ( Table 5 ). The reasons for the dose reduction of oxaliplatin did not differ between female patients or male patients treated with SOX (Table 6 ).
| Efficacy
In female patients, the median OS was 14.4 mo for SOX and 12. 
| D ISCUSS I ON
Leukopenia, neutropenia, nausea, and vomiting during the 1st cycle of SOX treatment, and vomiting and stomatitis during the 1st cycle of CS treatment were more frequently observed in female patients compared with male patients. In contrast, thrombocytopenia developed more often in male patients compared with female patients.
However, no significant sex-related difference was observed in the incidence of subjective adverse reactions such as diarrhea because with men (P = .0083). 16 This higher plasma 5-FU concentration was significantly related to severer neutropenia and stomatitis. 17 More than 80% of a given dose of 5-FU is rapidly catabolized to dihydrofluorouracil by DPD, the rate-limiting enzyme of pyrimidine metabolism, and to inactive dihydrouracil. 7 Toxicity from 5-FU in women was found in a recent study to be independent of DPYD genotype. Female patients had a two-fold higher risk for severe 5-FU-related toxicity compared with male patients and toxicity in women was independent of DPYD genotype because the OR for toxicity of 41.8 (95% CI, 9.2-190, P < .0001) in men with DPYD polymorphism was much higher than the OR of 1.33 (95% CI, 0.34-5.2, P = .68) in women. In addition, analysis from the same study of DPD expression and activity in the human liver did not reveal any sex-related differences. Evidence for methylation of the DPYD promotor in the same DNA from the same human liver was not found. 5 Pretherapeutic dihydrouracil concentration was significantly higher in female colorectal cancer patients compared with male patients, however the dihydrouracil/uracil ratio did not differ according to sex. A high level of uracil in females TA B L E 4 The incidence of any grade of nausea and vomiting by S-1 plus oxaliplatin (SOX) and S-1 plus cisplatin (CS) might therefore be associated with hematologic toxicity after 5-FU-based chemotherapy.
Another recent study has shown that global capecitabine toxicities were associated with rare, functional DPYD alleles 2846T>A
(minor allele frequency, 0.6%) and *2A (IVS14 + 1G>A, 0.4%) (combined OR, 5.51; P = .0013), the common TYMS polymorphism 5′VNTR2R/3R (47%), and a 3′UTR 6-bp Indel (31%) (combined OR, 1.31; P = 9.4 × 10 −6 ). 8 The higher incidence of 5-FU-related toxicities is difficult to explain by these rare DPYD variants. In total, 3-5% of Caucasians have reduced DPD activity, 18 however DPYD variants in the Japanese population are somewhat different from the previously reported Caucasian variants. DPYD alleles 2303C>A and 103G>T might play important roles in 5-FU-related toxicity for Japanese patients. 19 The sensitivity of DPYD genetic Tegafur is converted to 5-FU mainly by CYP2A6, and polymorphisms in CYP2A6 are thought to be related to 5-FU toxicity. 22 In addition, previous studies have suggested that CYP2A6 activity is higher in women and could be induced by estradiol via ERα, although further studies are required to confirm this suggestion. 23 Sex differences are well known in disease manifestations
and treatment effects such as in autoimmune or cardiovascular diseases, and reaction to vaccines. Despite these insights, the X chromosome is scrutinized less often in the current era of population genetics analyses due to unique statistical challenges, 24 although genome analyses of sex chromosomes could resolve some profound medical questions such as described here. The reason for the higher incidence of thrombocytopenia in male patients treated with CS therapy could not be clearly understood.
Thrombocytopenia after CS was not correlated with body mass index, this result differed from that of a previous study on cisplatin-based therapy.
11
In our study, no statistically significant relationship between treatment effects and sex was observed, although the incidence of with aprepitant should be considered because of the higher incidence of nausea and vomiting in SOX and vomiting in CS. It is difficult to reduce the starting dose of SOX for female patients due to their higher incidence of adverse events compared with male patients and because severe toxicities were rarely induced by SOX with 100 mg/ m 2 of oxaliplatin. 15 Conversely, the oxaliplatin dose should rather be increased to the recommended dose of 130 mg/m 2 , as proposed by the phase I/II trial on SOX, 25 along with full supportive antiemetic therapy for male patients. In conclusion, incidences of sex-related differences in adverse reactions during treatment with SOX and CS were confirmed in the G-SOX study. Further fundamental research studies are warranted to pursue the underlying cause. 
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